Jasper Therapeutics
Filed with the SEC on · accession 0001213900-26-117230
JSPR filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved -8.0% by the first close after the filing.
Jasper Therapeutics announced the results of its tender offer to purchase all outstanding warrants at $0.324 in cash per warrant, which expired on November 7, 2026.
Close before
$16.86
Nov 6, 2026
First close after
-7.96%
$15.52
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for JSPR, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for JSPR?
Click hereJSPR filed a 8-K (Tender offer). Jasper Therapeutics announced the results of its tender offer to purchase all outstanding warrants at $0.324 in cash per warrant, which expired on November 7, 2026.
A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
JSPR closed at $16.86 before the filing and $15.52 on Nov 9, 2026 (-7.96%).
Get alerts when JSPR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days